2021Research SquareOpen access

The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation

Yas Arimi, Narges Zamani, Mamak Shariat, Hossein Dalili

Open full text 2 citations

Abstract

Abstract Background: Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods: This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results: The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008) and requiring more respiratory support (71% versus 50%, p = 0.002) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion: the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.

Open-access reader

About this research paper

What this paper is about

Abstract Background: Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods: This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results: The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008) and requiring more respiratory support (71% versus 50%, p = 0.002) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion: the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract Background: Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods: This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results: The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008) and requiring more respiratory support (71% versus 50%, p = 0.002) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion: the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.

Key concepts: Betamethasone, Medicine, Gestation, Respiratory distress, Pediatrics, Retrospective cohort study, Obstetrics, Gestational age

Related papers

Back to paper searchBrowse research topicsOriginal source
The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation — Research Paper | ScholarLens